Indications
Hypertension
Telmisartan is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
It may be used alone or in combination with other antihypertensive agents
Cardiovascular Risk Reduction
Telmisartan is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk developing major cardiovascular events who are unable to take ACE inhibitors.
High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with the evidence of end-organ damage. Telmisartan can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy).
Studies of telmisartan in this setting do not exclude the possibility that telmisartan may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves. Use of telmisartan with an ACE inhibitor is not recommended.

Contraindications
• In patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product
• Do not co-administer aliskiren with telmisartan in patients with diabetes mellitus or renal impairment (GFR 60 ml/min/1.73 m2)
• Second and third trimesters of pregnancy
• Biliary obstructive disorders
• Severe hepatic impairment

TELMIDROP-H Tablets
Each tablet contains:
Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg

Dosage Form
Tablet
Description
TELMIDROP-H is a combination of two drugs with antihypertensive properties: a thiazide diuretic, hydrochlorothiazide, and an angiotensin II receptor blocker (ARB), telmisartan.
Indication
Hypertension
TELMIDROP-H(telmisartan and hydrochlorothiazide) tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. This fixed dose combination is not indicated for initial therapy for the treatment of hypertension. TELMIDROP-H may be used alone or in combination with other antihypertensive agents.

Contraindications
• Patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, hydrochlorothiazide, or any other component of this product.
• Hypersensitivity to other sulfonamide-derived substances (Since hydrochlorothiazide sulfonamide-derived medicinal product.
• Patients with anuria
• Second and third trimesters of pregnancy
• Cholestasis and biliary obstructive disorders
• Severe hepatic impairment
• Severe renal impairment (creatinine clearance (30 ml/min)
• Refractory hypokalemia, hypercalcemia
• Do not co-administer aliskiren with TELMIDROP-H in patients with diabetes mellitus or renal impairment (GFR ) 60 ml/min/1.73 m2)